SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff amid weakness in AI-infrastructure stocks has put its heavy debt burden, financing costs and insider selling at the center of the debate; a Goldman Sachs upgrade and reported ARK buying have not eased the concern for many traders. Bears warn of dilution or default, while bulls point to contracted AI-compute demand and see buying opportunities, leaving the stocks support levels in sharp focus.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is dominating discussion, with traders citing successive share unlocks and insider selling, a TD Cowen price-target cut, and concerns about OpenAI customer concentration and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are averaging down.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending, with CEO Hock Tans warning that some AI investing resembles gambling adding to concerns. Bears see his comments and AI-credit risks as reasons for continued weakness, while bulls argue demand and Broadcoms fundamentals remain intact and view the decline as a buying opportunity.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention as the S&P 500 rebounds after a tech-led selloff, with investors watching upcoming major-company earnings for signs the recovery can hold. Traders are split between viewing the move as a relief bounce and expecting further downside, amid concerns about AI spending and debt, oil prices, and weak market breadth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center expansion, heavy capital spending and weak free cash flow could strain its credit profile, amid broader doubts about AI infrastructure financing and demand. Many traders remain bearish after the selloff, while others argue Oracles cloud business and backlog can eventually generate returns; speculation about financing arrangements and an upcoming investor event also appears.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. The firm’s products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits, and embedded graphics. The company was founded by Wallace C. Kou in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

SIMO is drawing attention for its growth in AI and data-center storage, particularly boot-drive shipments and MonTitan enterprise SSD controllers, alongside strong results and an upbeat outlook. Many traders see room for further growth, while others point to sharp share-price swings, technical weakness and dilution concerns tied to convertible notes.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths third-quarter earnings beat and raised full-year outlook, supported by improved medical-cost control, are driving attention. Traders are split between viewing the results as evidence of a turnaround and questioning whether the margin improvement will last, while many reacted to the stocks volatile, initially muted response to the report.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a steep AI-infrastructure selloff tied to concerns about neocloud financing, debt, and whether massive data-center spending will earn adequate returns, followed by a volatile rebound. Traders are split between viewing the decline as an oversold buying opportunityoften arguing NBIS is better positioned than CoreWeaveand expecting rallies to fade as sector and market uncertainty persists.

Aventus Network

AVT is drawing attention as traders watch a volatile, thinly traded rebound for a breakout, focusing on trading volume and resistance levels. Aventus Clouds decentralized-compute and enterprise-appchain updates provide a bullish project narrative, but traders remain divided over whether momentum can persist amid low liquidity and selling pressure.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led relief rally after a sharp AI-related selloff has put QQQ in focus, with traders debating whether the volatile rebound signals recovery or is a temporary bounce. Upcoming megacap earnings are a key test, while concerns about AI infrastructure spending and weak market breadth sustain bearish views.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.read more...

Arbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback

(RTTNews) - Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent s...

Arbutus Biopharma Launches $230 Mln Share Buyback Via Dutch Auction; Shares Up In Pre-market

(RTTNews) - Arbutus Biopharma Corp. (ABUS) Friday announced a plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders...

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Equity

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.


MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.


ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week

Arbutus expects to receive around $179 million from Moderna. 


Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopharma among other stocks also falling.read more...

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - What's Next...

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Bearish Sentiment

<ul class="summary-bullets"><li>The company said it will fund the repurchase with cash in hand.</li><li>The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.</li><li>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data.</li></ul>Shares of Arbutus Biopharma Corporation (ABUS) surged over 10% in pre-market trading on Friday after the firm announced its intent to repurchase up to $230 million of its common shares.Arbutus Biopharma said it will repurchase the common shares at a purchase price of not less than $5 per share and not more than $5.75 per share, in cash, less any applicable withholding taxes and without interest.The company said it will fund the repurchase with cash in hand. The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.If Friday’s pre-market level holds, the stock will hit its July highs.<h2 class="st-heading-2">International Lawsuits</h2>Last month, the company, along with its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer Inc., BioNTech SE and certain of their affiliates.“We, alongside our exclusive licensee Genevant, will continue to vigorously enforce our rights against infringers, including Pfizer and BioNTech,” said Arbutus Biopharma CEO Lindsay Androski.“Our March 2026 settlement with Moderna, and the July 2026 initial payment under that settlement, were critical milestones in establishing for the world what most of the scientific community already knew: Arbutus’ lipid nanoparticle technology inventions opened the doors to an entirely new world of therapeutic treatments using nucleic acids,” she added.<h2 class="st-heading-2">ABUS’ Q2 At A Glance</h2>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data. The firm reported a loss of $0.03 per share compared to an estimated $0.02.Arbutus Biopharma ended the quarter with cash, cash equivalents, and investments in marketable securities of $92.6 million.<h2 class="st-heading-2">What Retail Thinks About ABUS</h2>On Stocktwits, retail sentiment continued to trend in the ‘extremely bullish’ territory amid high message volume.Stocktwits users expect the stock to rise to at least $6.5. It is currently trading close to $5.3, according to the pre-market rate.<stembedurl>https://stocktwits.com/Gugger/message/662506759</stembedurl><stembedurl>https://stocktwits.com/punktdot/message/662504166</stembedurl>The stock has gained nearly 33% in the last year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-issues-biggest-ever-recall-in-china-here-s-what-the-ev-maker-will-look-to-fix/cZYBMr6RJNn">Tesla Issues Biggest Ever Recall In China – Here’s What The EV Maker Will Look To Fix</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.

Roivant Sciences Ltd

ProShares Ultra Russell2000

Vanguard Russell 2000 Growth ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$4.23
Prev Close	$4.22
Open	$4.24
Dividend Yield	0.00%
50-Day Moving Average	$4.80
Beta	0.94
Avg. Volume	6.92M
PE Ratio	5.40

52-Week High	$5.45
52-Week Low	$3.50
Market Capitalization	$836.01M
EPS (Annual)	-$0.1748
Price to Book	3.23
Revenue Per Employee	$741,210.53

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABUS Fundamentals